MorphoSys AG (ETR:MOR)‘s stock had its “neutral” rating reaffirmed by J P Morgan Chase & Co in a research report issued on Monday, July 17th.
A number of other research analysts have also recently issued reports on the stock. Independent Research GmbH set a €77.00 ($90.59) target price on shares of MorphoSys AG and gave the company a “buy” rating in a research note on Monday, July 17th. Goldman Sachs Group, Inc. (The) set a €55.00 ($64.71) target price on shares of MorphoSys AG and gave the company a “neutral” rating in a research note on Monday, July 17th. HSBC Holdings plc set a €59.00 ($69.41) target price on shares of MorphoSys AG and gave the company a “neutral” rating in a research note on Friday, July 14th. Commerzbank Ag set a €76.00 ($89.41) target price on shares of MorphoSys AG and gave the company a “buy” rating in a research note on Friday, July 14th. Finally, Berenberg Bank set a €68.00 ($80.00) price target on shares of MorphoSys AG and gave the company a “buy” rating in a report on Friday, July 14th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. MorphoSys AG has an average rating of “Buy” and a consensus target price of €69.57 ($81.85).
Shares of MorphoSys AG (ETR MOR) traded down 0.671% during trading on Monday, reaching €56.121. The company had a trading volume of 4,188 shares. The firm has a 50-day moving average of €62.27 and a 200-day moving average of €57.58. The company’s market cap is €1.63 billion. MorphoSys AG has a 12-month low of €35.72 and a 12-month high of €70.90.
TRADEMARK VIOLATION WARNING: This piece was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.com-unik.info/2017/08/11/morphosys-ag-mor-earns-neutral-rating-from-j-p-morgan-chase-co-updated-updated-updated.html.
About MorphoSys AG
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
What are top analysts saying about MorphoSys AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MorphoSys AG and related companies.